Our Pipeline

We continuously develop and expand our robust pipeline to address patients' unmet medical needs. Our pursuit of new medicines is fueled by the scientific curiosity of our employees, a willingness to examine new ideas, and the pairing of existing information with novel concepts.

Please note that the medicines in the pipeline below are currently under clinical trial investigation and are not yet approved.
* As of July 2026

Pipeline Chart

Pipeline/Category
Cancer type
Phase
Country/Region
  • Breast Cancer
    Breast Cancer
  • Lung Cancer
    Lung Cancer
  • Colorectal Cancer
    Colorectal Cancer
  • Ovarian Cancer
    Ovarian Cancer
  • Hematologic Cancer
    Hematologic Cancer
  • Gastric Cancer
    Gastric Cancer
  • Esophageal Cancer
    Esophageal Cancer
  • Hepatocellular Carcinoma (HCC)
    Hepatocellular Carcinoma (HCC)
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
    Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Melanoma
    Melanoma
  • Pancreatic Cancer
    Pancreatic Cancer
  • Prostate Cancer
    Prostate Cancer
  • Renal Cell Carcinoma (RCC)
    Renal Cell Carcinoma (RCC)
  • Urothelial-Bladder Cancer
    Urothelial-Bladder Cancer
  • Other Solid Tumors Cancer
    Other Solid Tumors Cancer

Notes

Orphan drug designation (designated in at least one country/region among JP, US)：Orphan drug designation (designated in at least one country/region among JP, US)
Breakthrough Therapy Designation (US)：Breakthrough Therapy Designation (US)
Project in oncology that is planned to be submitted for approval in some countries/regions based on the results of Phase2 trials：Project in oncology that is planned to be submitted for approval in some countries/regions based on the results of Phase2 trials
Fast Track Designation (US)：Fast Track Designation (US)
Rare Pediatric Disease Designation (US)：Rare Pediatric Disease Designation (US)
ADC: antibody-drug conjugate, AGA: actionable genomic alterations, AML: acute myeloid leukemia, BC: breast cancer, BCL: B cell lymphoma, BTC: biliary tract cancer, CPS: combined positive score, CRPC: castration-resistant prostate cancer, EC: endometrial cancer, ESCC: esophageal squamous cell carcinoma, ES-SCLC: extensive stage-small cell lung cancer, ET: endocrine therapy, FP: fluoropyrimidine, GC: gastric cancer, HBL: hepatoblastoma, HCC: hepatocellular carcinoma, HR: hormone receptor, ICI: immune checkpoint inhibitor, MIUC: muscle invasive urothelial carcinoma, NBL: neuroblastoma, NSCLC: non-small cell lung cancer, OST: osteosarcoma, PBC: platinum-based chemotherapy, pMMR: mismatch repair proficient, r/r: relapse or refractory, RMS: rhabdomyosarcoma, SCLC: small cell lung cancer, TBA: to be announced, TC: tumor cells, THP: taxane (paclitaxel or docetaxel) + trastuzumab + pertuzumab, TNBC: triple negative breast cancer, TPD: targeted protein degradation, TPS: tumor proportion score, UC: urothelial carcinoma, WT: Wilms tumor